International Bioprocessing and Biologics Forum

Bioprocessing is the development and manufacturing pipeline by which therapeutic agents such as engineered recombinant proteins, viral gene therapy vectors, and other nanoparticle-based technologies are produced at levels required for commercial distribution. To achieve this end, large-scale cultures using engineered cell lines are grown in bioreactors or through other scalable approaches. These are constantly being refined and evolved to increase volume, product yield, and efficiency. The adoption of next-generation bioprocessing is reaching a decisive moment as biopharmaceutical companies are seeking new manufacturing methods that are essential to the industry's continued growth and innovation. It is more important than ever for the bioprocessing community to connect with one another, share ideas, and strategize. Our event will offer unique insights through intensive research with key industry figures, combined with presentations and panel discussions to bring in-depth and informative content.

Today’s bioprocessing is the base of different emerging industries and technologies, including the production of therapeutic stem cells, gene therapy vectors, and new vaccines. Advances in bioprocessing are of special interest to the industry as they highly shorten the development timeline, improve the final product, and increase the productivity of Bio-manufacturing facilities.

In this conference, leaders in biopharmaceutical production will investigate the latest technologies and manufacturing strategies for next-generation biologics and advanced therapies. It will mainly focus on the main challenges within the field, assessing innovative solutions such as continuous bioprocessing, SUTs, data integrity, PAT, and the implementation of industry 4.0, all of which aim to increase the efficiency and yield of therapeutic production whilst maintaining high-quality standards.

The International Bioprocessing and Biologics Forum will bring together more than 150+ industry experts from Large Pharma with interest in biotech, biotech, biopharmaceutical companies, contract manufacturing organizations, academic & research institutes, regulatory authorities, and solution providers, to discuss the latest developments, cutting-edge technologies, new challenges and opportunities in bioprocessing and best manufacturing practices to make better biologic drugs cheaper and faster!. So, what’s on the agenda for this year? Here’s a snapshot of what’s in store on this year’s program:

Evolution of Bioprocessing

Next Generation of Biologics Manufacturing

Gene Therapy at the Dawn of a New Era

Impact of Stress Factors on Protein Drug Products

LCMS Methods in Biological Formulation Development and in Quality Control

3D Printed Chromatography for Intensification of Downstream Processing of Biologics

Digital Twins for the Acceleration of the Bioproduct Life Cycle

How synbio at scale will disrupt the manufacturing of futures